AMGN Trading Analysis - 10/09/2026 10:44 AM — TRU-SENTIMENT

News Headlines & Context:

Recent general-knowledge headlines and context for AMGN (separate from data-driven analysis below):

• Amgen reported Q2 2026 results in early August with modest top-line growth led by obesity and inflammation pipelines; shares dipped post-print before stabilizing.
• In September 2026, AMGN saw a sharp volley of analyst commentary after a brief clinical hold on a secondary asset was lifted, contributing to elevated volatility.
• Amgen's board declared a quarterly dividend of $2.52 (yield ~2.5%), with ex-dividend in August 2026 already passed.
• No confirmed near-term FDA binary catalyst before the next major options expiration (2026-11-20); pipeline updates expected at medical conferences in late Q4.
• Macro backdrop of lower-rate expectations has supported large-cap biopharma multiple expansion, loosely aligning with the bullish options flow seen in embedded data.

Fundamental Analysis

Based strictly on provided FUNDAMENTALS data: Trailing P/E is 25.10 with trailing EPS of 16.22. Market cap is 222,929,605,200.00 and shares outstanding 540,632,000.00. Dividend yield is 2.47% with rate 10.08 and ex-date 2026-08-21. Beta is 0.11 (very low systemic risk). 52-week high 447.03 and low 288.00. Institutional ownership 60.81%. Average volume 3,074,000.00 and historical volatility 40.14%.

Revenue growth (YoY), gross/operating/net margins, ROE, Debt/Equity, Free Cash Flow, PEG, forward P/E, and analyst target price are null in the data and cannot be assessed. Valuation via trailing P/E 25.10 is the only multiple available; no sector peer P/E or PEG provided for comparison. Fundamental strength shows low beta and stable dividend; concern is missing profitability and leverage metrics. Fundamentals (stable large-cap, low beta) loosely support the technical recovery from September lows, but no earnings trend or target price confirms direction.

Current Market Position

Current price per indicators is 406.56 (2026-10-08 close 406.56; minute bars show 2026-10-09 10:15 last close 411.33). Recent daily action: fell from 444.12 (2026-09-03) to 374.46 low (2026-09-16), recovered to 424.37 (2026-09-29), then eased to 406.56. Intraday 2026-10-09 minute bars: opened 409.97, ranged 407.31–412.75, closed 411.33 at 10:15, showing mild upward intraday momentum from 409.97 to 412.75 high before pullback.

Technical Analysis

SMA 5 (405.24) above SMA 20 (400.31) signals short-term bullish alignment; price below SMA 50 (411.37) shows medium-term recovery incomplete. RSI 62.22 indicates moderate bullish momentum, not overbought. MACD histogram +0.14 (macd 0.70 > signal 0.56) confirms bullish crossover. Bollinger mid 400.31, price 406.56 sits just above mid, upper 431.08 acts as resistance. 30-day range high 445.81 / low 374.46; price near 38th percentile of range, below midpoint.

True Sentiment Analysis (Delta 40-60 Options)

Options flow sentiment is Bullish. Call dollar volume 32,520.00 vs put 12,585.00; call pct 72.10%, put pct 27.90%. Contracts: 43 calls / 19 puts across 9 call trades / 3 put trades. Total analyzed 2,024, true sentiment 12 (0.60% filter). Pure directional conviction skews bullish near-term; no divergence from technical uptrend (both positive).

Call Volume: $32,520.00 (72.1%) Put Volume: $12,585.00 (27.9%) Total: $45,105.00

Key Price Levels (Observational Only)